Pfizer Hosts Annual Meeting of Shareholders

NEW YORK–(BUSINESS WIRE)– The board of directors of Pfizer Inc. today declared a 30-cent
second-quarter 2016 dividend on the company’s common stock, payable June
1, 2016, to shareholders of record at the close of business on May 13,
2016. The second-quarter 2016 cash dividend will be the 310^th
consecutive quarterly dividend paid by Pfizer.

“In 2015, we returned nearly $13.1 billion to shareholders through
dividends and share repurchases,” said Ian Read, chairman and chief
executive officer. “In 2016, we continue to enhance shareholder value
through our dividend increase announced in December 2015 and our
accelerated share repurchase program executed in March 2016. In
addition, we remain focused on strengthening our innovative and
established businesses, and advancing our commercial and late-stage
pipeline, while maintaining the financial flexibility to pursue
attractive business development and other shareholder friendly capital
allocation opportunities.”

Preliminary results from the Annual Meeting of Shareholders held today
indicate that the company’s 11 director nominees were re-elected to
one-year terms and that shareholders ratified the selection of KPMG LLP
as Pfizer’s independent registered public accounting firm for the 2016
fiscal year. In addition, shareholders voted in support of the
board-sponsored proposal to approve, on an advisory basis, the
compensation of the company’s named executive officers.

In other voting, four shareholder proposals were not approved by the
shareholders.

The final results are subject to verification by the independent
election inspectors. The final results will be reported on a Form 8-K to
be filed by Pfizer with the Securities and Exchange Commission in the
next few days.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. For more information, please visit us at www.pfizer.com.
In addition, to learn more, follow us on Twitter at @Pfizer and
@Pfizer_News, LinkedIn, YouTube and like us on Facebook at
Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of
April 28, 2016. The Company assumes no obligation to update
forward-looking statements contained in this release as a result of new
information or future events or developments.

This release contains forward-looking information about the Company’s
actions to enhance shareholder value, including their potential
benefits, that involves substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. Risks and uncertainties include, among other
things, the uncertainties inherent in research and development; the
uncertainties inherent in business and financial planning, including,
without limitation, risks related to Pfizer’s business and prospects,
adverse developments in Pfizer’s markets, or adverse developments in the
U.S. or global capital markets, credit markets or economies
generally that could significantly impact Pfizer’s ability to implement,
or realize the benefits of, any business development or capital
allocation opportunity; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2015 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results,” as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160428006426/en/